# Prevention of Cardiac Dysfunction During Breast Cancer Therapy

Study · id `cardio:ct-nct03760588` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03760588](<https://clinicaltrials.gov/study/NCT03760588>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03760588

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 138 participants.

## Technical summary

Registry record NCT03760588. Randomized; quadruple masking; primary purpose prevention. Start 2019-01-31 (actual); primary completion 2024-09-05 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase: Phase 2
- Enrolled: 138 participants (enrolled count; ClinicalTrials.gov record NCT03760588, source copy `cardio:ctgov-nct03760588-2025-02-12`, retrieved 2026-10-26)
- Started: 2019-01-31 (actual) (ClinicalTrials.gov record NCT03760588, source copy `cardio:ctgov-nct03760588-2025-02-12`, retrieved 2026-10-26)
- Primary completion: 2024-09-05 (actual) (ClinicalTrials.gov record NCT03760588, source copy `cardio:ctgov-nct03760588-2025-02-12`, retrieved 2026-10-26)
- Completion: 2024-09-05 (actual) (ClinicalTrials.gov record NCT03760588, source copy `cardio:ctgov-nct03760588-2025-02-12`, retrieved 2026-10-26)
- Countries: Norway (ClinicalTrials.gov record NCT03760588, source copy `cardio:ctgov-nct03760588-2025-02-12`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03760588-2025-02-12`, retrieved 2026-10-26)

## The registry's words

- Brief title: Prevention of Cardiac Dysfunction During Breast Cancer Therapy
- Acronym: PRADAII
- Condition: Breast Cancer Female
- Condition: Heart Failure
- Intervention (Drug): Sacubitril/valsartan
- Lead sponsor: Torbjorn Omland
- Lead sponsor class: OTHER
- Collaborator: University Hospital, Akershus
- Collaborator class: OTHER
- Collaborator: Oslo University Hospital
- Collaborator class: OTHER
- Collaborator: University Hospital of North Norway
- Collaborator class: OTHER
- Collaborator: St. Olavs Hospital
- Collaborator class: OTHER
- Collaborator: Helse Stavanger HF
- Collaborator class: OTHER\_GOV
- Collaborator: Klinbeforsk
- Collaborator class: OTHER
- Collaborator: Norwegian Cancer Society
- Collaborator class: OTHER
- Collaborator: Novartis
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Sacubitril/valsartan (combination) (`cardio:sacubitril-valsartan`)
- Registry lists this organization as a collaborator: University Hospital, Akershus (`cardio:org-university-hospital-akershus`)
- Registry lists this organization as a collaborator: Oslo University Hospital (`cardio:org-oslo-university-hospital`)
- Registry lists this organization as a collaborator: University Hospital of North Norway (`cardio:org-university-hospital-of-north-norway`)
- Registry lists this organization as a collaborator: St. Olavs Hospital (`cardio:org-st-olavs-hospital`)
- Registry lists this organization as a collaborator: Novartis (`cardio:novartis`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Sacubitril/Valsartan and Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy: The PRADA II Randomized Clinical Trial (`cardio:pubmed-40884047`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: a1c1e8aca223fe86ce8108f4b0b90a8bbaa52cc51ec5c68b24affb4bcec48511
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
